alpha-aminopyridine has been researched along with dactolisib in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 27 (96.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Buckley, AF; Cho, YJ; Eroshkin, A; Febbo, PG; Korshunov, A; McLendon, RE; Miller, CR; Moore, CE; Northcott, PA; Pei, Y; Pfister, SM; Read, TA; Schmitt, EM; Sun, JL; Taylor, MD; Tewari, AK; Wang, J; Wechsler-Reya, RJ; Westbrook, TF; Witt, H | 1 |
| Bachmann, E; Galle, PR; Khillimberger, K; Linnig, M; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Hussien, K; Kelly, CJ; Muschel, RJ | 1 |
| Lee, M; Pellegata, NS; Reubi, JC; Waser, B | 1 |
| Gao, X; Jia, S; Lee, SH; Loda, M; Maira, SM; Roberts, TM; Signoretti, S; Stack, EC; Wu, X; Zhao, JJ | 1 |
| Beaven, A; Dave, SS; Fan, A; Jima, DD; Liu, Q; Love, C; McKinney, MS; Patel, A; Smith, J; Walsh, K | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Boukouris, AE; Buitrago-Molina, LE; Hegermann, J; Kirstein, MM; Kühnel, F; Manns, MP; Marhenke, S; Orlik, J; Pothiraju, D; Schütt, J; Vogel, A | 1 |
| Antón, P; Arribas, J; Baselga, J; Eichhorn, PJ; García-García, C; Hahn, WC; Ibrahim, YH; Kim, SY; Marlow, S; Parra, JL; Pérez-Garcia, J; Prat, A; Prudkin, L; Rodríguez, O; Sánchez, G; Scaltriti, M; Serra, V | 1 |
| Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L | 1 |
| Badura, S; Falkenburg, JH; Liebermann, M; Nijmeijer, BA; Ottmann, OG; Pfeifer, H; Ruthardt, M; Tesanovic, T; Wystub, S | 1 |
| Anthony, L; Campbell, K; Elliott, VA; Evers, BM; Harris, JW; Kim, JT; Li, J; Mustain, WC; Song, J; Townsend, CM; Valentino, JD; Wang, C; Weiss, H; Zaytseva, YY | 1 |
| Ashton, TM; Fokas, E; Hussien, K; Kannan, P; Kelly, CJ; Muschel, RJ; Pearson, N; Shipley, RJ; Stratford, M | 1 |
| Dan, S; Kong, D; Yamazaki, K; Yamori, T | 1 |
| Aymerich, M; Beà, S; Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Salaverria, I; Xargay-Torrent, S | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, MA; Caffarra, C; Cavazzoni, A; Cretella, D; Falco, A; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, CA; Madeddu, D; Petronini, PG; Quaini, F; Rossetti, P; Saccani, F; Tiseo, M | 1 |
| Adetchessi, T; Barlier, A; Chinot, O; Defilles, C; Dufour, H; Enjalbert, A; Figarella-Branger, D; Fuentes, S; Germanetti, AL; Graillon, T; Lisbonis, C; Metellus, P; Mohamed, A; Roche, PH | 1 |
| Bari, A; Civallero, M; Cosenza, M; Ferri, P; Pozzi, S; Sacchi, S | 1 |
| Al-Awar, R; Babichev, Y; Boutros, PC; Datti, A; Dickson, BC; Gladdy, RA; Isaac, M; Kabaroff, L; Prakesch, M; Sun, RX; Uehling, D; Venier, R | 1 |
| Auger, C; Chanal, M; Chevallier, P; Fonteneau, G; Honnorat, J; Jouanneau, E; Lucia, K; Monteserin Garcia, JL; Rachwan, A; Raverot, G; Raverot, V; Theodoropoulou, M; Trouillas, J | 1 |
| de Gruijl, TD; de Haas, RR; Huijts, CM; Quiles Del Rey, M; Santegoets, SJ; van der Vliet, HJ; Verheul, HM | 1 |
| Chen, S; Ma, WJ; Wu, XZ; Zhang, HR; Zhang, JH; Zhang, WL | 1 |
| Almeida, J; Blanco, B; Corchete, LA; Del Cañizo, C; García-Briñón, J; Herrero-Sánchez, MC; Inogés, S; Rodríguez-Serrano, C; San Miguel, JF; San Segundo, L; Santos-Briz, Á | 1 |
| Chaire, V; Fourneaux, B; Italiano, A; Karanian, M; Laroche-Clary, A; Lucchesi, C; Pineau, R | 1 |
| Castellano, D; Chakravartty, A; Chi, KN; Csonka, D; de Bono, J; Dirix, L; Fizazi, K; Gravis, G; Machiels, JP; Maier, J; Massard, C; Mellado, B; Mita, A; Turri, S | 1 |
| Chen, B; Kraus, D; Palasuberniam, P | 1 |
| Andonova, T; Bersani, C; Dalianis, T; Holzhauser, S; Kostopoulou, ON; Lange, BKA; Ohmayer, A; Wickström, M | 1 |
| Tulsawani, R; Vohora, D; Vyas, P | 1 |
1 trial(s) available for alpha-aminopyridine and dactolisib
| Article | Year |
|---|---|
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asthenia; Chills; Diarrhea; Fever; Humans; Hyperglycemia; Imidazoles; Kallikreins; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinolines; Stomatitis; Vomiting | 2017 |
27 other study(ies) available for alpha-aminopyridine and dactolisib
| Article | Year |
|---|---|
An animal model of MYC-driven medulloblastoma.
Topics: Aminopyridines; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Cerebellar Neoplasms; Cerebellum; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Genes, p53; Imidazoles; Medulloblastoma; Mice; Morpholines; Neural Stem Cells; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinolines; TOR Serine-Threonine Kinases | 2012 |
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; HCT116 Cells; HT29 Cells; Humans; Imidazoles; Irinotecan; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Topics: Aminopyridines; Animals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Feasibility Studies; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Spheroids, Cellular; Time Factors; Treatment Outcome | 2012 |
Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adult; Aged; Aminopyridines; Animals; Apoptosis; Cell Proliferation; Cell Survival; Female; Gastrointestinal Agents; Gene Knockdown Techniques; Humans; Imidazoles; Male; Morpholines; Neurites; PC12 Cells; Pheochromocytoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Receptors, G-Protein-Coupled; Receptors, Gastrointestinal Hormone; RNA Interference; Secretin; Signal Transduction; Transcription, Genetic | 2012 |
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
Topics: Aminopyridines; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Castration; Imidazoles; Male; MAP Kinase Kinase Kinases; Mice; Mice, Transgenic; Morpholines; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Testosterone | 2013 |
PAK1 mediates resistance to PI3K inhibition in lymphomas.
Topics: Aminopyridines; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Profiling; Humans; Imidazoles; Lymphoma; Morpholines; Oligonucleotide Array Sequence Analysis; p21-Activated Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Small Molecule Libraries; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Topics: Aminopyridines; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Respiration; Cisplatin; Doxorubicin; Everolimus; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Molecular Targeted Therapy; Morpholines; Open Reading Frames; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Everolimus; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Topics: Aminopyridines; Antineoplastic Agents; Drug Synergism; Everolimus; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lymphocytes; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Naphthyridines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Drug Synergism; Humans; Imidazoles; Male; Mice; Mitogen-Activated Protein Kinases; Morpholines; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.
Topics: Aminopyridines; Animals; Cell Hypoxia; Cell Line, Tumor; HCT116 Cells; Humans; Imidazoles; Mice; Morpholines; Neoplasms; Oxygen Consumption; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Spheroids, Cellular; TOR Serine-Threonine Kinases | 2014 |
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Topics: Aminopyridines; Antineoplastic Agents; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Humans; Imidazoles; Indazoles; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinolines; Sulfonamides; Triazines | 2014 |
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Topics: Aminopyridines; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Interleukin-4; Interleukin-6; Lymphoma, Mantle-Cell; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcriptome; Tumor Microenvironment | 2014 |
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Topics: Aminopyridines; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Imidazoles; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Cell Cycle; Cell Survival; Drug Therapy, Combination; Everolimus; Female; Humans; Imidazoles; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Morpholines; Neurofibromin 2; Octreotide; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Receptors, Somatostatin; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Activity of BKM120 and BEZ235 against Lymphoma Cells.
Topics: Aminopyridines; Antineoplastic Agents; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Imidazoles; Lymphoma, Non-Hodgkin; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Quinolines; Reactive Oxygen Species; Signal Transduction | 2015 |
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Imidazoles; Leiomyosarcoma; Mice, Inbred NOD; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Reproducibility of Results; TOR Serine-Threonine Kinases | 2016 |
Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
Topics: Aminopyridines; Animals; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Humans; Imidazoles; Morpholines; Phosphatidylinositol 3-Kinases; Phosphorylation; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.
Topics: Aminopyridines; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Cells, Cultured; Cytokines; Everolimus; Flow Cytometry; Humans; Imidazoles; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Sirolimus; T-Lymphocytes, Regulatory; TOR Serine-Threonine Kinases | 2016 |
[Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; beta Catenin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imidazoles; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2016 |
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Topics: Aminopyridines; Animals; Cell Proliferation; Graft vs Host Disease; Imidazoles; Lymphocyte Activation; Mice; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; T-Lymphocytes; TOR Serine-Threonine Kinases | 2016 |
Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Leiomyosarcoma; MAP Kinase Kinase Kinases; Mechanistic Target of Rapamycin Complex 2; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinolines; Rapamycin-Insensitive Companion of mTOR Protein; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
Topics: Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Humans; Imidazoles; Mice; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Verteporfin; Xenograft Model Antitumor Assays | 2017 |
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Child, Preschool; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Infant; Infant, Newborn; Male; Morpholines; Mutation; Neuroblastoma; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrazoles; Quinolines; Receptor, Fibroblast Growth Factor, Type 3 | 2019 |
Dual Targeting by Inhibition of Phosphoinositide-3-Kinase and Mammalian Target of Rapamycin Attenuates the Neuroinflammatory Responses in Murine Hippocampal Cells and Seizures in C57BL/6 Mice.
Topics: Aminopyridines; Animals; Apoptosis; Cell Line; Cytokines; Hippocampus; Imidazoles; Immunosuppressive Agents; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Morpholines; Neuroinflammatory Diseases; Oxidative Stress; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Seizures; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2021 |